Possible Associations Between Antioxidant Enzyme Polymorphisms and Metabolic Abnormalities in Patients with Schizophrenia

Overview

Journal Neuropsychiatr Dis Treat

Publisher Dove Medical Press

Specialty Psychiatry

Date 2013 Nov 9

PMID 24204153

Citations 6

Authors

Junji Saruwatari

Norio Yasui-Furukori

Ryoko Kamihashi

Yuki Yoshimori

Kentaro Oniki

Shoko Tsuchimine

Madoka Noai

Yasushi Sato

Taku Nakagami

Norio Sugawara

Manabu Saito

Akira Fujii

Ayami Kajiwara

Shuichi Mihara

Yasuhiro Ogata

Sunao Kaneko

Kazuko Nakagawa

Affiliations

Soon will be listed here.

Abstract

Background: This study investigated the possible association between common and potentially functional polymorphisms of antioxidant enzymes and metabolic abnormalities in patients with schizophrenia.

Methods: The possible associations of the glutathione S-transferase (GST) M1 null and GSTT1 null genotypes, and the superoxide dismutase 2 (SOD2) Val16Ala polymorphism with the risks of being overweight and having metabolic syndrome were examined using a logistic regression analysis in 154 schizophrenic Japanese patients and 203 controls.

Results: Among smokers with schizophrenia, the risks of being overweight and having decreased high-density lipoprotein cholesterol were significantly higher in those with the GSTM1 null genotype than in those with the present genotype (odds ratio 3.20 and 3.15, P=0.03 and P=0.04, respectively), while among nonsmokers with schizophrenia, the risk of an abnormal waist circumference was lower in those with the GSTM1 null genotype (odds ratio 0.34, P=0.04). The risk of a decreased high-density lipoprotein cholesterol level was significantly higher in patients with the combined GSTM1 null and GSTT1 present genotypes than in those with the present genotypes of both genes (odds ratio 3.60, P<0.01). The SOD2 Val16Ala polymorphism was not associated with risk of metabolic abnormalities in either group.

Conclusion: The present study suggests that the GSTM1 null genotype, in combination with smoking status or GSTT1 genotype, might be associated with the metabolic abnormalities in patients with schizophrenia.

Citing Articles

/ Polymorphisms and Schizophrenia Risk: A New Method for Quality Assessment and a Systematic Review.

Liu H, Xu Y, Peng J Neuropsychiatr Dis Treat. 2023; 19:97-107.

PMID: 36643584 PMC: 9833125. DOI: 10.2147/NDT.S376942.

Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms.

Karahalil B, Elkama A, Ak M, Nemutlu E Toxicol Res (Camb). 2022; 11(3):547-556.

PMID: 35782649 PMC: 9244978. DOI: 10.1093/toxres/tfac034.

Glutathione S-transferase gene polymorphisms (GSTT1 and GSTM1) and risk of schizophrenia: A case-control study in Chinese Han population.

Zhang X, Yang J, Liu X, Zhao G, Li X, Xun G Medicine (Baltimore). 2020; 99(36):e21918.

PMID: 32899025 PMC: 7478483. DOI: 10.1097/MD.0000000000021918.

Genetic Polymorphisms of Glutathione-Related Enzymes (GSTM1, GSTT1, and GSTP1) and Schizophrenia Risk: A Meta-Analysis.

Kim S, Kang S, Chung J, Park H, Cho K, Park M Int J Mol Sci. 2015; 16(8):19602-11.

PMID: 26295386 PMC: 4581314. DOI: 10.3390/ijms160819602.

An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia.

Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T Clin Psychopharmacol Neurosci. 2015; 13(1):62-7.

PMID: 25912539 PMC: 4423155. DOI: 10.9758/cpn.2015.13.1.62.

References

De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A . Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006; 2:14. PMC: 1533826. DOI: 10.1186/1745-0179-2-14. View

Tian C, Fang S, Du X, Jia C . Association of the C47T polymorphism in SOD2 with diabetes mellitus and diabetic microvascular complications: a meta-analysis. Diabetologia. 2010; 54(4):803-11. DOI: 10.1007/s00125-010-2004-5. View

Boden R, Edman G, Reutfors J, Ostenson C, Osby U . A comparison of cardiovascular risk factors for ten antipsychotic drugs in clinical practice. Neuropsychiatr Dis Treat. 2013; 9:371-7. PMC: 3653763. DOI: 10.2147/NDT.S40554. View

Vancampfort D, Probst M, Scheewe T, De Herdt A, Sweers K, Knapen J . Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia. Psychiatry Res. 2012; 207(1-2):25-32. DOI: 10.1016/j.psychres.2012.09.026. View

Bitanihirwe B, Woo T . Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev. 2010; 35(3):878-93. PMC: 3021756. DOI: 10.1016/j.neubiorev.2010.10.008. View

Srihari V, Phutane V, Ozkan B, Chwastiak L, Ratliff J, Woods S . Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr Res. 2013; 146(1-3):64-8. PMC: 3622848. DOI: 10.1016/j.schres.2013.01.014. View

Verma S, Subramaniam M, Liew A, Poon L . Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry. 2009; 70(7):997-1000. DOI: 10.4088/JCP.08m04508. View

Lear S, Toma M, Birmingham C, Frohlich J . Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. Metabolism. 2003; 52(10):1295-301. DOI: 10.1016/s0026-0495(03)00196-3. View

Grundy S, Cleeman J, Daniels S, Donato K, Eckel R, Franklin B . Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112(17):2735-52. DOI: 10.1161/CIRCULATIONAHA.105.169404. View

10.

Ginsberg G, Smolenski S, Hattis D, Guyton K, Johns D, Sonawane B . Genetic Polymorphism in Glutathione Transferases (GST): Population distribution of GSTM1, T1, and P1 conjugating activity. J Toxicol Environ Health B Crit Rev. 2010; 12(5-6):389-439. DOI: 10.1080/10937400903158375. View

11.

Teranishi M, Uchida Y, Nishio N, Kato K, Otake H, Yoshida T . Polymorphisms in genes involved in oxidative stress response in patients with sudden sensorineural hearing loss and Ménière's disease in a Japanese population. DNA Cell Biol. 2012; 31(10):1555-62. PMC: 3458618. DOI: 10.1089/dna.2012.1631. View

12.

Santl Letonja M, Letonja M, Ikolajevic-Starcevic J, Petrovic D . Association of manganese superoxide dismutase and glutathione S-transferases genotypes with carotid atherosclerosis in patients with diabetes mellitus type 2. Int Angiol. 2012; 31(1):33-41. View

13.

Wu J, Kosten T, Zhang X . Free radicals, antioxidant defense systems, and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 46:200-6. DOI: 10.1016/j.pnpbp.2013.02.015. View

14.

De Hert M, Detraux J, van Winkel R, Yu W, Correll C . Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011; 8(2):114-26. DOI: 10.1038/nrendo.2011.156. View

15.

Barter P . HDL-C: role as a risk modifier. Atheroscler Suppl. 2011; 12(3):267-70. DOI: 10.1016/S1567-5688(11)70885-6. View

16.

Hayes J, Flanagan J, Jowsey I . Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005; 45:51-88. DOI: 10.1146/annurev.pharmtox.45.120403.095857. View

17.

Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J . Oxidative stress during treatment with first- and second-generation antipsychotics. J Neuropsychiatry Clin Neurosci. 2005; 17(2):227-31. DOI: 10.1176/jnp.17.2.227. View

18.

Schorr S, Slooff C, Bruggeman R, Taxis K . The incidence of metabolic syndrome and its reversal in a cohort of schizophrenic patients followed for one year. J Psychiatr Res. 2009; 43(13):1106-11. DOI: 10.1016/j.jpsychires.2009.03.002. View

19.

Fukai T, Ushio-Fukai M . Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal. 2011; 15(6):1583-606. PMC: 3151424. DOI: 10.1089/ars.2011.3999. View

20.

Newcomer J . Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007; 68 Suppl 1:20-7. View